Lamotrigine (LTG) was used in 12 patients with juvenile myoclonic epilepsy (JME) who either had sodium valproate (VPA) side effects or did not wish to take VPA. Five patients are now fully controlled on LTG monotherapy. Side-effects were corrected by VPA withdrawal or reduction except for severe weight gain. In three patients it was not possible to withdraw VPA due to the re-emergence of myoclonus, suggesting LTG-VPA synergism. Two patients had successful pregnancies whilst taking LTG. Lamotrigine is a useful alternative in the management of JME.
It is accepted that sodium valproate (VPA) is the antiepileptic drug (AED) of choice in the treatment of juvenile myoclonic epilepsy (JME)'. However, as with all drugs, VPA has side-effects 2 which may on occasion make its use unacceptable to the patient. In a previously reported group of 36 patients with JME, the main VPA side effects were weight gain, hair loss and fluid retention "~. In view of the report by Timmings and Richens 4 on the efficacy of lamotrigine (LTG) in JME, 12 patients with JME and significant VPA sideeffects were commenced on LTG with the intent of replacing VPA where possible. The present short communication describes this clinical experience.
PATIENTS AND METHODS
There were 12 patients, all female, aged 29.3 + 7.7 (18-40 years) in whom VPA was either producing unacceptable side-effects or who did not wish to take VPA (Table 1) .
Lamotrigine was commenced with a dose of 12.5mg every other day, increasing the dose fortnightly until either seizure control was achieved or in those patients with pre-existing complete seizure control an ITG dose (200-300mg/day) at which it was felt safe to begin reducing VPA dosage, was reached.
The aims of treatment were to obtain complete seizure control (no overt seizures and no myoclonus) and if possible to reduce or withdraw VPA so as to diminish or abolish VPA sideeffects.
RESULTS
The 12 patients had epilepsy for 16.2 + 8.5 (4-31 years). Seven patients were receiving VPA monotherapy, three carbamazepine (CBZ) monotherapy, one patient was on CBZ, clobazam (CLB) and sulthiame and the final patient was on no medication. She had previously been on VPA, gained 18 kg in weight and ceased taking VPA as a result.
Two patients ceased LTG. In the first patient who was taking CBZ with ongoing myoclonus, LTG produced profound insomnia at a dose of 4.3 mg/kg/day. Despite complete seizure control and CBZ withdrawal, the insomnia was such that the patient ceased LTG, declined to take VPA and went back onto CBZ. The second patient, a 30-year-old woman whose family exhibited a marked illness behaviour pattern, became seizure free at a LTG dose of 1.5mg/kg/day. She developed headaches which may have been LTG related, but before it was possible to discuss the management of this problem, her mother ceased LTG abruptly.
At the onset of LTG treatment, four patients were completely controlled, four had generalized tonic-clonic seizures (GTCS), three had only myoclonus on awakening and one patient had absences and myoclonus. At the time of review, seven patients had complete control, three have myoclonus on awakening when sleep deprived only and the two patients who ceased LTG are as they were prior to LTG. In the 10 ongoing patients, LTG has been used for 1.5 + 0.4 (1-2.0 years) in a dose of 5.0 + 1.3 (2.6-6.9 mg/kg/day).
With respect to pre-existing AEDs, VPA was withdrawn in three patients who are now on LTG monotherapy along with two patients in whom CBZ was withdrawn. In three other patients, VPA could be reduced by about 50%, but further reductions led to the re-emergence of myoclonus. Attempts to increase LTG further so as to again reduce VPA, produced side-effects (dizziness, ataxia and headache). Only one other patient exhibited LTG side-effects with swelling of the lips and tongue at a daily LTG dose of 50 mg + VPA 800 mg. This settled spontaneously over two weeks. No patients developed a rash.
Turning to the pre-existing side effects, the outcome of LTG treatment is shown in Table 1 . The two patients with moderate weight gain and hair loss are now side-effect free, as is the patient with fluid retention. In the two patients with marked weight gain it has been possible to reduce VPA dosage, but not withdraw it. To date there has been no weight loss, which in large part relates to the dietary habits of these two patients.
Finally two patients, one on LTG monotherapy and the others taking VPA 400 mg/day and LTG 5.5 mg/kg/day have had successful pregnancies. There were no seizures or myoclonus during the pregnancies and both infants are normal and healthy.
DISCUSSION
This brief report describes the use of LTG in the management of JME. The observation that five patients are totally controlled with LTG monotherapy (average dose 340 mg/day; range, 300-400 mg) supports the report by Timmings and Richens 4 of the efficacy of LTG in this epilepsy syndrome. Further, it has been shown that in patients with VPA side-effects of moderate weight gain, hair loss and fluid retention can have these side-effects alleviated by adding LTG allowing VPA reduction or withdrawal. Substantial weight gain is more difficult to alleviate although in the two such patients in this report, lifestyle issues and dietary habits are a major problem. It might therefore not be expected that VPA dosage reduction alone would be effective in weight reduction. There is little published data on the use of LTG in pregnancy, the present report documents two patients who had uncomplicated pregnancies with normal infants.
Finally, there were three patients in whom it was possible to reduce VPA, but not withdraw it, due to the re-emergence of myoclonus. These patients were taking on a daily basis, 400 mg LTG + 1000 mg VPA, 300 mg LTG + 400 mg VPA and 500 mg LTG + 200~ng VPA, respectively. Whilst it is accepted that sodium valproate increases serum lamotrigine concentrations 6, this does not appear to be the explanation for the therapeutic interaction seen in these three patients in whom increasing LTG produced side-effects and decreasing VPA allowed myoclonus to re-appear. The observa-tions suggest a therapeutically interesting pharmacodynamic interaction between VPA and LTG, supporting similar observations by other authors 7'8. This interaction needs to be explored further to maximize the therapeutic advantage that can be obtained from these two drugs.
Lamotrigine is effective in the management of JME and offers possibilities for patients with VPA side-effects or who do not wish to take VPA. Further monotherapy studies vs. VPA are required to assess cost-efficacy.
